Quotient Limited prices Initial Public Offering

Quotient Limited (Nasdaq:QTNTU), an established, commercial-stage diagnostics company, has announced the pricing of its initial public offering of 5,000,000 units, each consisting of one ordinary share and one warrant to purchase 0.8 of one ordinary share, at a price of $8.00 per unit.

The warrants will be exercisable at an exercise price of $8.80 per whole ordinary share. In addition, Quotient has granted the underwriters a 30-day option to purchase up to an additional 750,000 units at the initial public offering price. All of the units are being offered by Quotient.

The units are expected to begin trading today, April 25, 2014, on the NASDAQ Global Market under the ticker symbol “QTNTU.” The ordinary shares and warrants comprising the units will begin trading separately on the NASDAQ Global Market under the symbols “QTNT” and “QTNTW,” respectively, on the first trading day following the expiration of the underwriters’ 30-day over-allotment option, at which time trading of the units will be suspended and the units will be delisted. The offering is expected to close on April 30, 2014, pending customary closing conditions.

UBS Investment Bank, Baird and Cowen and Company are acting as joint book-running managers for the offering.

A registration statement relating to these securities has been filed with, and declared effective by, the Securities and Exchange Commission (SEC) on April 24, 2014.

Quotient Limited is an established, commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the development and commercialization of innovative tests for blood grouping and serological disease screening. Quotient is developing MosaiQ, its proprietary technology platform, to offer a breadth of diagnostic tests that is unmatched by any commercially available transfusion diagnostic instrument platform. Quotient’s operations are based in Edinburgh, Scotland; Newtown, Pennsylvania; and Eysins (near Geneva), Switzerland.

CLICK HERE TO REGISTER FOR FREE ON ADVFN, the world's leading stocks and shares information website, provides the private investor with all the latest high-tech trading tools and includes live price data streaming, stock quotes and the option to access 'Level 2' data on all of the world's key exchanges (LSE, NYSE, NASDAQ, Euronext etc).

This area of the ADVFN.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Plc. ADVFN Plc does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ADVFN.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Authors may or may not have positions in stocks that they are discussing but it should be considered very likely that their opinions are aligned with their trading and that they hold positions in companies, forex, commodities and other instruments they discuss.

WHAT IS ADVFN?

ADVFN covers all things stock market.

From the news and opinion pieces on pages like this to share discussion forums, charting tools, financials, live share prices and Level 2, order book data

If you trade or invest ADVFN has the tools you need to make the right decisions.

• 

  101 Ways to Pick Stock Market Winners

  You need the number one bestselling investment guide, the definitive text for day traders, investors and stock pickers.

• 

  The Death of Wealth

  Dissecting the global economy and the financial markets, the book lays out the evidence for the next economic game changer: the Death of Wealth.

• 

  Francois Normandeau

• 

  Glenmore Investments

• 

  Ben Branson

• 

  Ella Mason